(Total Views: 682)
Posted On: 08/17/2024 7:27:46 PM
Post# of 148876
This is the last company, I'd be a mole for hire @ now.
No way....Jose.
Good thing about the CRO issue now, is this new Mgr role reports to Mr. Meddling.
Who's now been with Cytodyn for 3 yrs. So he's been looking forward to milestone & seeing the CRO put in real work this time. Looking forward to the CRO he helps on the vetting. Highly doubt it's the post Amarex one from the Recknor stint.
But there's no fooling or bullshitting this guy.
Internally or externally:
Mr. Meidling joined CytoDyn in March of 2021 as Senior Director of Portfolio and Project Management and in May of 2022 was appointed Senior Director of Clinical Operations. Prior to joining CytoDyn, Mr. Meidling spent nearly 22 years at Merck where he held various positions of increasing responsibilities in Drug Development. He was a director in Clinical Pharmacology and Translational Medicine and led the Pharmacogenomics and Biorepository group before moving on to become the site lead for Merck’s Kenilworth facility and was responsible for Merck’s Early-Stage Development portfolio and resource planning.
___________
Nice believing the company press releases.
What a stunning turn-around that's happening.
No way....Jose.
Good thing about the CRO issue now, is this new Mgr role reports to Mr. Meddling.
Who's now been with Cytodyn for 3 yrs. So he's been looking forward to milestone & seeing the CRO put in real work this time. Looking forward to the CRO he helps on the vetting. Highly doubt it's the post Amarex one from the Recknor stint.
But there's no fooling or bullshitting this guy.
Internally or externally:
Mr. Meidling joined CytoDyn in March of 2021 as Senior Director of Portfolio and Project Management and in May of 2022 was appointed Senior Director of Clinical Operations. Prior to joining CytoDyn, Mr. Meidling spent nearly 22 years at Merck where he held various positions of increasing responsibilities in Drug Development. He was a director in Clinical Pharmacology and Translational Medicine and led the Pharmacogenomics and Biorepository group before moving on to become the site lead for Merck’s Kenilworth facility and was responsible for Merck’s Early-Stage Development portfolio and resource planning.
___________
Nice believing the company press releases.
What a stunning turn-around that's happening.
(6)
(0)Scroll down for more posts ▼
